Suppr超能文献

相似文献

4
Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
Kidney Int. 2017 Nov;92(5):1206-1216. doi: 10.1016/j.kint.2017.03.026. Epub 2017 May 20.
5
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.
6
Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
J Nephrol. 2018 Dec;31(6):961-966. doi: 10.1007/s40620-018-0545-8. Epub 2018 Oct 24.
7
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol. 2012 Mar;7(3):479-86. doi: 10.2215/CJN.09500911. Epub 2012 Feb 16.
8
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.
9
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Clin J Am Soc Nephrol. 2016 May 6;11(5):803-811. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.
10

引用本文的文献

3
Depressive Symptoms in Adults with Autosomal Dominant Polycystic Kidney Disease.
Kidney360. 2025 Apr 1;6(4):561-572. doi: 10.34067/KID.0000000683. Epub 2024 Dec 23.
4
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.
7
Mental Health and Autosomal Dominant Polycystic Kidney Disease: A Narrative Review.
Kidney360. 2024 Aug 1;5(8):1200-1206. doi: 10.34067/KID.0000000000000504. Epub 2024 Jul 8.
8
9
Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.
Kidney Med. 2023 Nov 27;6(1):100755. doi: 10.1016/j.xkme.2023.100755. eCollection 2024 Jan.
10
Cardiovascular Manifestations and Management in ADPKD.
Kidney Int Rep. 2023 Aug 4;8(10):1924-1940. doi: 10.1016/j.ekir.2023.07.017. eCollection 2023 Oct.

本文引用的文献

1
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.
2
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol. 2012 Mar;7(3):479-86. doi: 10.2215/CJN.09500911. Epub 2012 Feb 16.
3
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
N Engl J Med. 2010 Aug 26;363(9):820-9. doi: 10.1056/NEJMoa0907419. Epub 2010 Jun 26.
4
Evaluation and management of pain in autosomal dominant polycystic kidney disease.
Adv Chronic Kidney Dis. 2010 May;17(3):e1-e16. doi: 10.1053/j.ackd.2010.01.005.
5
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
J Am Soc Nephrol. 2010 Jun;21(6):1052-61. doi: 10.1681/ASN.2009121291. Epub 2010 Apr 29.
6
The HALT polycystic kidney disease trials: design and implementation.
Clin J Am Soc Nephrol. 2010 Jan;5(1):102-9. doi: 10.2215/CJN.04310709.
7
"An evil heritage": interview study of pain and autosomal dominant polycystic kidney disease.
Pain Manag Nurs. 2009 Sep;10(3):134-41. doi: 10.1016/j.pmn.2009.03.002.
9
Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.
Clin J Am Soc Nephrol. 2009 Mar;4(3):560-6. doi: 10.2215/CJN.02410508. Epub 2009 Mar 4.
10
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.
Clin J Am Soc Nephrol. 2006 Jan;1(1):148-57. doi: 10.2215/CJN.00330705. Epub 2005 Oct 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验